Researchers from Rice University and Baylor College of Medicine have identified a “glyco-immune” checkpoint inhibitor that could help treat bone cancer metastasis for breast cancer survivors.
Research from the University of Pittsburgh explains why metastatic uveal melanoma is resistant to conventional immunotherapies and how adoptive therapy, which involves growing a patient’s T cells outside the body before reinfusing them, can successfully treat this rare and aggressive cancer.
